Real-world evidence supporting the use of advanced hybrid closed loop in poorly controlled type 1 diabetes patients
Authors' conclusion
Our findings support a-HCL utilization across all patients, particularly in poorly controlled type 1 diabetes patients.
Study context
- Population
- T1D patients at University Hospital Zurich, Switzerland, who transitioned from predictive low glucose suspension (PLGS) or standard hybrid closed-loop (s-HCL) to advanced hybrid closed loop (a-HCL) between January 2020 and December 2021
- Participants
- 71 patients
- Exposure
- Advanced HCL vs prior PLGS or standard HCL
- Outcome
- Glycemic metrics pre vs post a-HCL
Methodological detailssingle-centre, pre-post comparison
- Single-centre
- Pre-post comparison
Main finding
As reported in the abstract
HbA1c, pre-a-HCL vs post-a-HCL (mean ± SD; p < 0.001)
7.2 ± 0.9 % to 6.8 ± 0.5 %
Sensor glucose (SG), pre-a-HCL vs post-a-HCL (mean ± SD; p < 0.001)
8.8 ± 1.4 mmol/L to 7.8 ± 0.8 mmol/L
Time above range (TAR), pre-a-HCL vs post-a-HCL (p < 0.001)
26.3 % to 17.3 %
Time in range (TIR), pre-a-HCL vs post-a-HCL (p < 0.001)
68.5 % to 79.8 %
Observational data: associations, not effects.
Further findings
Subgroups with greatest improvement
- Improvements most pronounced with higher baseline HbA1c, SG, coefficient of variation (CV) and lower TIR, and BMI > 30 kg/m²
Original publication
Real-world evidence supporting the use of advanced hybrid closed loop in poorly controlled type 1 diabetes patients. Diabetes Res Clin Pract. Published 8 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →